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Abstract Immune cells are known to affect clinical
outcome in colorectal cancer. Subsets of immune cells can
both support and inhibit immunological interaction with
tumor cells. We examined the clinical impact of T cells that
are supposed to be responsible for the down regulation of a
T cell response: regulatory T cells or Tregs. The study
population (n=76) consisted of a random population of
colorectal cancer patients who did not receive any (neo-)
adjuvant therapy, with a median follow-up time of 7.3 years
(range 0.1–23.1 years). Expression of FoxP3 was used as
an immunohistochemical marker to identify Tregs. We
considered FoxP3+ cells present in tumor stroma and
tumor epithelium separately, and related results to clinical
outcome and to data on CD8+ immune cell infiltration that
we previously obtained in the same patient cohort. All
samples showed presence of Foxp3+ cells and in the
majority of the patients (85.5%) these cells were also
present in the tumor epithelial compartment. A relative high
level of Foxp3+ cells in the tumor epithelium was
significantly related to down regulation of HLA Class I
expression (p-value 0.03). There was a trend, but no
significant relation, towards a longer overall survival
(p-value; 0.084) and disease-free survival (p-value; 0.073)
when high levels of Foxp3+ cells were present in the tumor
epithelium. More importantly, the ratio of CD8+/Foxp3+
cells did show a significant correlation with distant-
recurrence-free survival. This was the case for both Foxp3+
cells specifically located in the tumor epithelium (p-value
0.024) as well as in the stroma compartment (p-value 0.018).
Unfortunately due to the small sample size the ratios did not
retain their statistical significance in multivariate analysis.
These results provide further evidence that local interactions
in the cancer microenvironment between tumor cells and
immune cells are not only determined by tumor cell-related
factors like HLA expression, but also by interactions among
immune cells.
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Introduction
The process of tumor development in colorectal cancer
(CRC) is one of the most studied and best characterized
models of tumorigenesis in the world today. At least six
features can be identified that hallmark tumor growth and
development [1, 2]. Three of which are related to the
immune system. Tumor cells may acquire the ability to
thrive in a inflamed micro-environment, to evade immune
recognition and, to suppress immune reactivity [3]. The
adaptive immune system and its key players, especially
cytotoxic T Lymphocytes (CTL), play an important role in
controlling tumor growth and metastasis. Naito et al. were
the first to demonstrate that infiltrating CTL are a
prognostic factor in CRC [4]. Due to their genetic
instability, tumor cells may arise with a phenotype that
makes them less sensitive to immune surveillance, thus
escaping CTL recognition. This phenotype includes down
regulation or complete loss of one or more HLA class I
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alleles. This enables tumor cells to minimize their presen-
tation of tumor-associated antigens (TAA) and, therefore,
diminish their chance of recognition and subsequently
destruction by CTL [5–8]. Another mechanism to evade
immunosurveillance is to suppress immune reactivity by
attraction of immunosuppressive regulatory T cells (Tregs)
into the tumor micro-environment. Both, down regulation
of HLA class I, and presence of Tregs, have been shown to
be of clinical relevance in various types of solid tumors [9–
12]. CRC-related studies that describe HLA class I
expression in relation to clinical prognosis have, however,
rendered contrasting results. Some studies were not able to
determine any significant relation between HLA class I
expression and survival, while others did [13–16]. When a
significant relation could be established, a total lack of
HLA class I expression always resulted in more favorable
prognosis. This is probably due to the fact that HLA Class I
negative metastatic cells in the circulation will be targets for
destruction by Natural Killer (NK) cells that are abundantly
present in the circulation but not in solid tumors [17, 18].
Partial expression, however, was related to either a better or
worse prognosis compared to high expression [15, 16].
Similar, there are a variety of studies describing the
presence of Tregs in tumor tissue in relation to clinical
outcome. In case of ovarian cancer, three studies were able
to establish that high Treg infiltration was associated with a
poor prognosis [10, 19, 20]. In colorectal cancer, however,
4 studies describing the presence of Tregs in cancer tissues
have rendered contrasting results. Loddenkemper et al.
performed an analysis on 40 colorectal tumor samples and
could not establish a significant relation between the
presence of Foxp3+ Tregs or the ratio CD8+/Tregs with
outcome [21]. In contrary, a recently published study by
Suzuki et al., a predictive value of the intra-tumoral ratio of
CD8+ T cells and Foxp3+ Tregs could be established [22].
A third study by Salama et al. using a Tissue Micro Array
of 967 stage II and III CRC patients was able to
significantly correlate the presence of Tregs to clinical
outcome parameters [23]. High Foxp3+ Treg density in the
normal mucosa of patients was associated with a worse
prognosis, while a high density in the tumor tissue was
associated with improved survival. Finally, a study of Deng
et al. was able to significantly correlate the accumulation of
Foxp3+ Tregs in draining lymph nodes to disease [24]. The
latter four publications as well as the studies on the
significance of HLA Class I expression in colorectal cancer
all have in common that they were performed on mixed
study populations containing both adjuvant and non-
adjuvant treated, metastatic and non-metastatic patients
and patients of which tumor microsatellite status was often
not determined. Besides, the presence of Foxp3+ Tregs was
expressed in several ways; either as their presence in the
tumor epithelium, in the tumor stroma or as a ratio with
CD8+ cells. All these variations in study methods make it
difficult to recapitulate the results of these studies into one
overall conclusion. Therefore, the importance of HLA class
I expression and Foxp3+ Treg infiltration in relation to the
presence of CD8+ CTLs still remains to be determined in
CRC patients. The purpose of this study was to analyze
the presence of Foxp3+ Tregs and relate the data to the
data on infiltrating immune cells and HLA expression
that we have previously obtained in a random cohort of
patients, without adjuvant treatment [7]. The data on
Foxp3+ Tregs were also correlated with clinico-pathologic
variables such as TNM (Tumor Node Metastasis) classi-
fication, tumor differentiation grade and the tumors
microsatellite stability status (MSS/MSI), as well as with
outcome parameters such as overall survival (OS) and
disease free survival (DFS).
Patients and Methods
Patients
Between January 1980 and December 1992, 266 consecu-
tive patients underwent curative resection with post-
operative follow up for a colorectal adenocarcinoma at the
Leiden University Medical Center. Within this cohort,
previously described by Tollenaar et al. and Menon et al.,
76 patients were identified who did not receive any (neo-)
adjuvant therapy and of whom data was available on CD8+
lymphocyte infiltration, tumor microsatellite stability status
and HLA Class I expression [7, 15, 25]. CD8+ infiltration
was scored as the number of CD8+ leukocytes per tumor
area (leukocytes/mm2 tumor epithelium). The average
leukocyte infiltration of 25 fields per tumor section was
calculated and defined as the intraepithelial leukocyte
infiltration. In addition, leukocytes in the tumor stroma
and at the tumor margin were assessed semi quantita-
tively into ‘none–poor’ or ‘moderate–marked’ leukocyte
infiltration. The tumor microsatellite status was deter-
mined with MLH1-based immunohistochemistry. MLH1
expression was categorized as absent if the majority of
the tumor cells lacked nuclear MLH1 expression; this
suggests a microsatellite instable (MSI) tumor phenotype.
If nuclear MLH1 expression was present in the majority
of the tumor cells samples were indicated to be micro-
satellite stable (MSS).
HLA Class I expression was determined previously by
immunohistochemistry using the monoclonal antibodies
HCA2 and HC10 according to the defined standard method
of the International HLA and Immunogenetics Workshop
(IHIW) in which HCA2 and HC10 staining are scored in 5
categories. (0–5% positivity, 5–25% positivity, 25–50%
positivity, 50–75% positivity and 75–100% positivity). In
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66 out of the 76 (87%) tumors, both HCA2 and HC10
staining could be quantified and, therefore, were available
for evaluation of total HLA Class I expression. Three
groups were identified according to a standardized method
and defined as (1) HLA class I loss (staining of both HCA2
and HC10) was less than 5% of the tumor cells; (2) HLA
class I reduced expression (staining of either HCA2 or
HC10 was less than 50% of the tumor cells); and (3) HLA
class I expression (staining of both HCA2 and HC10 was
more than 50% of the tumor cells) [8].
Tumors were staged according to the TNM criteria [26].
Known tumor characteristics included differentiation grade,
Jass lymphocyte infiltration score, DNA microsatellite
status, and presence of mucinous characteristics. Median
follow- up was 7.3 years (range 0.1–23.1 years). Patient
and tumor- characteristics are shown in Table 1.
Immunohistochemistry
A Foxp3/laminin immunohistochemical double staining of
tumor sections was performed to evaluate the presence of
Foxp3+ regulatory T cells in both the epithelial and stromal
compartment of the primary tumors. FFPE (formalin-fixed
paraffin-embedded) tissue sections of 5 μm thickness were
prepared on aminopropylethoxysilane (APES)-coated slides
and dried at 37°C. Tissue sections were deparaffinized in
xylene, submerged in 0.3% hydrogen-peroxidase methanol
to block endogenous peroxidase, and rehydrated in a graded
ethanol series. For antigen-retrieval, tissues were soaked in
0.01 M citrate buffer (pH 6) at 100°C for 10 min. After
rinsing in PBS, tissues were incubated overnight with anti-
FOXP3 (1:300, ABCAM AB20034). On the second day,
Biotin-labeled Rabbit-anti-Mouse secondary antibody
(30 min, 1:200, DAKO) followed by Streptavidin-Biotin-
complex (30 min, 1:100, DAKO) was used for signal
amplification. After 5 min of soaking in a 0.05 M Tris-HCl
solution, tissues were developed for 10 min with 3,3-di-
amino-benzidine tetrahydrochloride (DAB) for visualiza-
tion. Next, tissues were transferred to a 0.01% trypsin
solution and soaked at 37°C for 10 min. Rabbit polyclonal
anti-laminin (1:50, Sigma L9393) was applied to the
sections for overnight incubation. Subsequently, tissues
were incubated with Biotin-labeled Swine-anti-Rabbit
(1:400, DAKO) for 30 min, followed by Streptavidin-
Biotin-complex (1:100, DAKO) for 30 min. A blue signal
was achieved by developing the tissue sections for 12 min
in a 4-chloro-1-naphtol solution. Methyl green was used for
nuclear counterstaining. Finally, all tissue sections were
dehydrated and mounted in Kaiser’s glycerol. FFPE
sections of tonsil and normal colon tissues were included
as positive controls for the Foxp3 and laminin staining and as
negative controls by replacing incubations with either the
primary antibody or secondary antibody bymock incubations.
Evaluation of the Immunohistochemistry
The number of Foxp3+ cells in primary colorectal tumor
tissues was microscopically evaluated by two independent
observers (ECMZ and AQvH). Microscopic evaluation was
done without previous knowledge of patient characteristics
or disease outcome. The laminin-staining served as demar-
cation to distinguish the epithelial from stromal tumor
Table 1 Clinico-pathological characteristics of the 76 patients median
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High expression 43 65.2
Reduced expression 18 27.3
Loss of expression 5 7.6
unknown 10 –
Table 1 shows the clinico-pathological characteristics of all of the 79
primary colorectal cancer patients included in this study
Yrs years, TNM Tissue Node Metastasis, MSS Micro Satellite Stable,
MSI Micro Satellite Instable, HLA Human Leukocyte Antigen
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compartments and other tissue. For counting, an ocular grid
was used at 100x magnification. First the total amount of
Foxp3+ cells (tot-Foxp3+) was counted in 5 randomly
chosen, separate grid fields (surface-area of 3 mm²) in each
tumor. This approach enabled to determine the number of
positive cells per mm2 tumor tissue. The tot-Foxp3+ count
was further subdivided according to location of the Foxp3+
cells: Foxp3+ cells located actually in the tumor epithelium,
which means there was direct contact with the tumor cells
and the Foxp3+ cells, were counted as tumor-Foxp3+ cells
(t-Foxp3+), and Foxp3+ cells located in the tumor stroma as
stromal-Foxp3+ cells (s-Foxp3+). Inter-observer conformity
was calculated using the intraclass correlation test. Intraclass
correlation coefficients for single measures were 0.93, 0.82
and 0.93 (p<0.001) for the tot-Foxp3+, the t-Foxp3+ and the
s-Foxp3+ cell counts respectively. Observer counts were
averaged and used to calculate the final t-Foxp3+ and s-
Foxp3+ counts and the t-Foxp3+/tot-Foxp3+ ratio for each
tumor sample. Previously determined number of CD8+ cells
present in the tumor epithelium (t-CD8+) were used to
calculate the t-CD8+/t- or s-Foxp3+ [7].
Statistical Analysis
Statistical analyses were performedwith SPSS software version
16.0 (SPSS Inc, Chicago, IL). To test whether the mean levels
of Foxp3+ cells differed between the tumor and the stroma
compartments theWilcoxon Signed ranks test was applied. The
Chi-squared test was used to evaluate associations between the
presence of t-Foxp3+ cells, s-Foxp3+ cells and the t-Foxp3+/
tot-Foxp3+ ratio and various clinico-pathologic parameters,
and HLA Class I expression and the presence of CD8+ cells.
For the survival analysis, date of surgery was used as the entry
date for analysis. The Kaplan-Meier method was used for
overall survival (OS), disease-free survival (DFS), distant-
recurrence-free survival (DRFS) and local-recurrence-free
Survival (LRFS) and the log-rank test for comparison of the
survival curves. OS, DFS, DRFS and LRFS were defined as
follows; date of any event of interest minus entry date. Hazard
ratios were calculated the Cox proportional hazards analysis for
uni- and multivariable analysis. Only parameters that were of
statistical significance in the univariate analysis were analyzed
in the multivariate model. Significance of hazard ratios was
tested with the Wald’s test. All statistical tests were two-tailed
with a 0.05 significance level.
Results
Immunohistochemistry
The laminin IHC double staining demarcated the tumor
epithelium from the stromal compartment within the
tumors. (Fig. 1) Therefore, the exact location and number
of the Foxp3+ cells within the tumor tissue could be
determined. For all 76 cases, Foxp3 infiltration data were
obtained. Foxp3+ cells were found to be present in the
stromal compartment of all tumors. In the majority of the
patients (85.5%) Foxp3+ cells were also present in the
tumor epithelium. The mean number of Foxp3+ cells in the
tumor epithelium (t-Foxp3+) was 0,25/mm2 with a range of
0–1.73, and in the tumor stroma (s-Foxp3+) 5.84/mm2,
ranging from 0,43–20,87. This was a significant difference
(p-value <0.000). Because the counts of both locations of
FoxP3+ cells were skewed to the right of the range, the
median was used for further analysis as a cut-off point for
the presence of Foxp3+ cells. The median was 0.133/mm2
for t-Foxp3 and 4.818/mm2 for s-Foxp3 respectively.
The numbers of CD8+ cells were previously determined
in the same patient cohort. As described in the study by
Menon et al., the cut-off used for the number of CD8+ cells
in the tumor epithelium (t-CD8+), was at the 75 percentile
(65 cells/mm2) [7]. The presence of CD8+ cells at the
tumor margin (m-CD8+) or tumor stroma (s-CD8+) was
scored qualitatively as either no or poor infiltration,
moderate, and marked infiltration. The scores in the entire
study population did not statistically significantly differ
from those of the patients used in this subset analysis.
Association of Presence and Location of Foxp3+ Cells
with Clinico-pathological Parameters, HLA Class I
Expression, and Presence of CD8+ Cells
Neither the presence of t-Foxp3+ or s-Foxp3+ showed a
significant correlation to any of the standard clinico-
pathological parameters (Table 2). Their presence was also
B
A
Fig. 1 A representative image of the Foxp3 and laminin double
staining. In which the laminin (blue) clearly demarcates the tumor
stroma from the tumor epithelium (light brown area). In this image
typical examples of epithelial Foxp3+ cells (a) and Foxp3+ cells in the
tumor stroma can be identified (b)
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not related to HLA class I expression status of the tumor.
The ratio of t-Foxp3+/tot-Foxp3+ did show a statistically
significant relationship with HLA class I expression. When
HLA class I expression was low, no expression or reduced
expression within the tumor, the ratio of t-Foxp3/tot-Foxp3
was higher at a p-value of 0.03 (Table 2). Patients with
reduced HLA class I expression were therefore more likely
to have relatively higher numbers of Foxp3+ cells in the
tumor epithelium compared to the number of s-Foxp3.
In concordance with the data previously shown by
Menon et al., the number of t-CD8+ cells significantly
correlated with tumor stage and was inversely correlated
with HLA status [7].
The presence of t-Foxp3+ cells or the ratio of t-Foxp3+/
tot-Foxp3+ cells did not show any statistical significant
relationship with the presence of CD8+ cells at any location
in the tumor. In contrast, the presence of s-Foxp3+ cells did
show a significant relation to the presence of CD8+ cells at
the tumor margin. When more CD8+ cells were present in
the tumor margin the number of Foxp3+cells in the stroma
also increased statistically significantly (p-value: 0.043,
Table 3).
Table 2 Presence of Foxp3+ Tregs in tumor compartments in relation to clinico-pathological characteristics and HLA status
Characteristic % s-Foxp3+ p-value % t-Foxp3+ p-value %t-Foxp3+/tot- Foxp3+ p-value
>median >median >median
Sex (n=76)
Male 52,3 0.642 47,7 0.941 52,3 0.642
Female 46,9 46,9 46,9
Age (n=76)
<65 years 47,4 0.913 52,6 0.910 47,4 0.913
65–70 years 44,4 44,4 44,4
70–75 years 52,6 42,1 52,6
>75 years 55 50 55
Tumor location (n=76)
Left colon 41,4 0.498 37,9 0.150 41,4 0.410
Right colon 55,2 44,8 51,7
Rectum 55,6 66,7 61,1
TNM Stage (n=76)
I 54,8 0.501 51,6 0.439 45,2 0.437
II 58,3 58,3 66,7
III 42,4 39,4 48,5
Differentiation (n=74)
Poor 46,3 0.505 53,7 0.426 58,5 0.243
Moderate 61,1 38,9 38,9
Well 42,9 35,7 35,7
Mucinous (n=69)
Yes 57,9 0.377 52,6 0.622 57,9 0.377
No 46 46 46
Jass Classification (n=69)
Absent-scarce 47,8 0.865 47.8 1.0 56,5 0.395
Moderate-marked 50 47.8 45,7
MSI status (n=76)
MSS 46 0.128 46 0.607 49,2 0.761
MSI 69,2 53,8 53,8
HLA status (n=66)
Reduced/loss 43,5 0.678 52,2 0.423 65,2 0.03
Expression 48,8 41,9 37,2
Table two shows the relation of either the presence of Foxp3 + cells in the tumor stroma (s-Foxp3+), in the tumor epithelia, (t-Foxp3+) and the
ratio t-Foxp3+/total amount of Foxp3 + (t-Foxp3+/tot-Foxp3+) present to clinico-pathological parameters and HLA expression. Presence is
expressed as the percentage of patients that showed levels of s-Foxp3+ and t-Foxp3+ or a ratio above the cut-off level set in all cases at the median
TNM Tissue Node Metastasis, MSS Micro Satellite Stable, MSI Micro Satellite Instable, HLA Human Leukocyte Antigen
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Association of the t-CD8+/Foxp3+ Ratio
with Clinico-pathological Parameters and HLA
Class I Expression
To determine whether the number of Foxp3+ cells
combined with the number of CD8+ cells was related to
clinico-pathological parameters or HLA Class I expression,
their ratio was calculated. This was performed for both t-
Foxp3+ and s-Foxp3+ cell counts. Absolute data on CD8+
cells was only available for the t-CD8+ counts. The ratio t-
CD8+/t-Fox3+ or t-CD8+/s-Foxp3+ could be determined
for 63 cases. The median t-CD8+/t-Foxp3+ ratio was 73,
median t-CD8+/s-Foxp3+ ratio was 4.03. Due to the
distribution of the data the median was used as a cut-off
point. Neither of these ratios was related to clinico-
pathological parameters or HLA class I expression (data
not shown).
Association of Foxp3+ Cells and the CD8+/Foxp3+
with Clinical Prognosis
The presence of t-Foxp3+ cells or s-Fop3+ cells was not
related to tumor recurrence (p-values of 0.598 and 0.446
respectively). Patients with high t-Foxp3+ cell counts
compared to patients with low t-Foxp3+ counts showed a
trend towards both a longer Overall Survival (OS) time
(122 months vs. 96,7 months, p=0.084) and a longer
Disease Free Survival (DFS) time (109 months vs.
83 months, p=0.073). (Figs. 2, and 3). Previously, Menon
et al. have shown that t-CD8+ cells was an independent
prognostic factor of a longer disease-free survival [7]. Also
the ratio of the number of t-CD8+ cells and number of t -
Foxp3+ cells (t-CD8+/t-Foxp3+) showed a trend towards a
longer OS time. A ratio above the median, indicating a relative
larger number of t-CD8+ cells compared to t-Foxp3+ cells,
was related to a longer OS time of 130 months compared to
87 months at a ratio below the median (p-value; 0.053). The
same trend was seen for DFS, however this was again not
significant at a p-value of 0.081 (Figs. 2, and 3). The t-CD8/
s-Foxp3+ ratio was never related to OS or DFS. Interestingly,
both the t-CD8+/t-Foxp3+ and t-CD8+/s-Foxp3+ ratio were
significantly related to Distant Recurrence Free Survival
(DRFS). Both ratios showed a longer DRFS time for patients
when above median: 214 months vs. 142 months for the t-
CD8+/s-Foxp3+ ratio at a p- value of 0.018, and 226 vs.
158 months for the t-CD8+/t-Foxp3+ ratio at a p-value of
0.024 (Fig. 4).
Univariate and Multivariate Analysis
Uni – and multivariate analysis was performed to calculate
hazard ratios, to identify whether the t-CD8+/t-Foxp3+ and
t-CD8+/s-Foxp3 ratios were independent of prognostic
significance for DRFS. Analysis included known risk
factors such as age, TNM stage, tumor microsatellite status,
etc. For the DRFS, advanced TNM stage as well as the t-
CD8+/t-Foxp3+ and s-Foxp+ ratios were statistically
significant predictors in the univariate analysis. The hazard
ratios for TNM stage II and III were 4,294 (CI95% 0,717–
25,713) and 8,125 (CI95% 1,847–36,533) respectively at a
p-value of 0.003. The hazard ratios of t-CD8+/t-Foxp3+ −and
s-Foxp3+ cells were 0.190 (p-value 0.034) and 0.294 (p-value
0.034). However neither of these parameters was able to retain
their value as an independent significant predictor of DRFS in
multivariate analysis (data not shown). Also for OS analysis,
univariate and multivariate analysis were executed with the
Table 3 Presence of CD8+ CTLS in the various tumor compartments related to the presence of Foxp3 positive cells
% s-Foxp3+ p-value % t-Foxp3+ p-value %t-Foxp3+/tot-Foxp3+ p-value
>median >median >median
t-CD8+(n=67)
Low 46% 0.183 46% 0.621 50% 0.834
High 64.7% 52% 47.1%
s-CD8+(n=67)
no-poor 41% 0.162 46.2% 0.698 51% 0.400
moderate 66.7% 55.6% 55.6%
marked 60% 40% 30%
m-CD8+ (n=64)
no-poor 35.3% 0.043 52% 0.422 52.9% 0.697
moderate 46.7% 40% 53.3%
marked 76.5% 40.8% 41.2%
Table three shows the relation of the presence of Foxp3 + cells in the tumor stroma (s-Foxp3+), in the tumor epithelium, (t-Foxp3+) and the ratio
t-Foxp3+/total amount of Foxp3+ cells (t-Foxp3+/tot-Foxp3+) present to the presence of CD8+ cells in either the tumor epithelium (t-CD8+), the
tumor stroma (s-CD8+) or the tumor margin (m-CD8+). The determination and qualification of the presence of CD8+ cells has been previously
described [7]
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same parameters. In univariate analysis only mucinous
differentiation showed a statistically significant relation to OS.
(HR 0.504; CI95% 0.288–0.882; p-value 0.016) This effect
did not remain in the multivariate analysis (data not shown)
Discussion
The ability of tumor cells to thrive in a chronically inflamed
microenvironment is only one of three important immune
system-related hallmarks of tumor growth and develop-
ment. Two other features also play a major role in the
process of tumorigenesis. First, tumors are able to develop
certain features that make it possible for them to evade
immune recognition [27]. Among others, these features
comprise down regulating or even complete loss of HLA
class I expression. This way, for the most part they lose the
capability to become recognized and attacked by the
immune system. Tumor cells may also be poorly immuno-
genic because of insufficient presence of TAA presentation
or co-activating signals. Secondly, tumor cells may evade
immune reactivity by restraining an anti-tumor immune
BA
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Fig. 2 Kaplan Meier graphs for
Foxp3 levels in the tumor
epithelium (t-Foxp3+) (a) and as
a ratio with CD8+ in the tumor
epithelium (t-CD8+/t-Foxp3+)
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response [5–8]. The latter currently gets a lot of attention in
tumor immunology as it has become clear that tumor cells
may attract immunosuppressive cells such as Foxp3+
regulatory T cells (Tregs). Tregs inhibit the development
of autoimmune responses, but also are capable of impeding
antitumor immune responses [28, 29]. In this study we were
able to identify and quantify both these features in
colorectal tumor samples. In addition we found that both
features were seemingly interconnected. The mechanism by
which Foxp3+ Tregs become attracted to the tumor
microenvironment remains yet to be discovered. Two
hypotheses can be postulated. Either tumor cells actively
attract these cells or the overall inflammatory character
induced by tumor growth also induces the influx of Tregs
into the tumor microenvironment. Our results showed that
down regulation of HLA class I was associated with a
relative higher level of epithelial Foxp3+ cells as compared
to the number of Foxp3+ cells in the tumor stromal
compartment. This seems to be contradicting, but may be
a reflection of an earlier anti-tumor immune reaction.
Possibly, tumor reactive CTL caused selective outgrow of
HLA loss tumor variances. The immune cells involved,
such as the Tregs and CD8+ cells, apparently remain
present as illustrated by our results.
Our data also illustrate the importance of the interplay
between various types of immune cells in the tumor
microenvironment in determining clinical outcome as neither
the presence of Foxp3+ cells nor CD8+ cells was statistically
significantly prognostic. Combined, however, the ratio of these
cells significantly predicted clinical outcome with respect to
distant recurrence of disease, suggesting a functional mutual
relationship. Previous data published on the effect of Foxp3+
cells in CRC patients is rather inconclusive with respect to
their prognostic relevance [21–24]. One of the reasons for
lack of consistency in the results may be variation in study
population size as the larger studies by Salama et al. and
Suzuki et al. both showed a relationship between Foxp3+ cell
presence in tumors and clinical prognosis, while studies on
smaller populations did not [22, 23]. The data presented here,
even though derived from a relative small patient cohort,
indicates that a more comprehensive approach is probably of
greater importance than large patient numbers. This approach,
combining data on two types of immune cells that are
expected to interact, but also tumor characteristics that may
interfere, will better show the involvement and clinical
relevance of the immune system in colorectal cancer. A
comparable approach was chosen by Loddenkemper et al.
and Suzuki et al., but in our study this approach was
extended by the incorporation of more data regarding key
elements of the process of tumor development [21, 22].
Tumor microsatellite status, and other tumor characteristics
that were previously shown to be of clinical importance,
including HLA class I status, were included in our analysis.
The major advantage of this comprehensive ‘mapping’
approach at the level of immune regulation in colorectal
cancer is the clinical applicability of the data, as the
information might be used to determine treatment allocation,
like suggested before. For example, a study by De Kruijf et
al. showed that the presence of Foxp3+ cells alone in breast
cancer patients had no prognostic value [9]. However, when
combined with level of HLA expression the data showed a
prognostic effect in adjuvant treated patients. It was postulat-
ed that counteraction of Tregs by chemotherapy allowed CTL
to affect tumor metastases development, but only when HLA
expression was intact [9]. Further research conducted in stage
III and IV adjuvantly treated patients will determine whether
such an effect is also present in CRC patients.
In conclusion, we were able to determine a prognostic effect
on disease recurrence free survival of the presence of Foxp3+
cells, in either the tumor stromal compartment or the tumor
epithelium, but only when combined with data on CD8+ cells.













Fig. 4 Kaplan Meier graphs for
Foxp3 levels in the tumor
epithelium (t-Foxp3+) (a) as a
ratio with CD8+ in the tumor
epithelium (t-CD8+/t-Foxp3+)
(b) in relation to Disease Free
Survival
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that shows the interplay between members of the immune
system in CRC patients. We hypothesize that studying even
more cell types and molecules involved, such as NK ligands,
co-stimulating molecules, and activating or suppressing cyto-
kines, will lead to a better understanding of the tumor-immune
system interaction. This will eventually help us to better predict
patient prognosis and will direct adjuvant treatment.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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